Pub. Date : 2013 Jul
PMID : 23735514
3 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. | AZD 6244 | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 2 | Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients with BRAF-mutant melanoma and in preclinical models when combined with chemotherapy. | AZD 6244 | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |
| 3 | INTERPRETATION: Selumetinib plus dacarbazine showed clinical activity in patients with BRAF-mutant cutaneous or unknown primary melanoma, reflected by a significant benefit in progression-free survival compared with placebo plus dacarbazine group, although no significant change in overall survival was noted. | AZD 6244 | B-Raf proto-oncogene, serine/threonine kinase | Homo sapiens |